Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Discontinued Operations: 2009-2013

Historic Cash from Discontinued Operations for Ligand Pharmaceuticals (LGND) over the last 4 years, with Dec 2013 value amounting to -$642,000.

  • Ligand Pharmaceuticals' Cash from Discontinued Operations was N/A to -$1.1 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$992,000, marking a year-over-year change of. This contributed to the annual value of -$642,000 for FY2013, which is 28.67% up from last year.
  • As of FY2013, Ligand Pharmaceuticals' Cash from Discontinued Operations stood at -$642,000, which was up 28.67% from -$900,000 recorded in FY2012.
  • Ligand Pharmaceuticals' 5-year Cash from Discontinued Operations high stood at $240,000 for FY2010, and its period low was -$3.2 million during FY2009.
  • Over the past 2 years, Ligand Pharmaceuticals' median Cash from Discontinued Operations value was -$771,000 (recorded in 2012), while the average stood at -$771,000.
  • Data for Ligand Pharmaceuticals' Cash from Discontinued Operations shows a peak YoY spiked of 107.59% (in 2010) over the last 5 years.
  • Over the past 4 years, Ligand Pharmaceuticals' Cash from Discontinued Operations (Yearly) stood at -$3.2 million in 2009, then spiked by 107.59% to $240,000 in 2010, then reached -$900,000 in 2012, then increased by 28.67% to -$642,000 in 2013.